Mirae Asset Global ETFs Holdings’s Nurix Therapeutics NRIX Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.2M	Sell	77,897 -1,428	-2%	-$23.7K	﹤0.01%	1433
2025 Q4	$1.51M	Buy	79,325 +39,227	+98%	+$564K	﹤0.01%	1299
2025 Q3	$371K	Sell	40,098 -4,907	-11%	-$51K	﹤0.01%	2015
2025 Q2	$514K	Sell	45,005 -4,799	-10%	-$51.9K	﹤0.01%	1808
2025 Q1	$593K	Buy	49,804 +5,286	+12%	+$88.4K	﹤0.01%	1775
2024 Q4	$838K	Buy	44,518 +5,899	+15%	+$135K	﹤0.01%	1641
2024 Q3	$870K	Buy	38,619 +9,044	+31%	+$205K	﹤0.01%	1619
2024 Q2	$617K	Buy	+29,575	New	+$461K	﹤0.01%	1720

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's NRIX Position: Q1 2026 in Review

Mirae Asset Global ETFs Holdings reduced its Nurix Therapeutics (NRIX) stake by 1.8% in Q1 2026, selling an estimated $23.7K and leaving 77,897 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1433.

Mirae Asset Global ETFs Holdings first reported a position in NRIX in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.51M in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

Mirae Asset Global ETFs Holdings held 77,897 shares of Nurix Therapeutics worth $1.2M as of Q1 2026.
Mirae Asset Global ETFs Holdings sold 1,428 Nurix Therapeutics shares in Q1 2026, an estimated $23.7K.
Nurix Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q1 2026, its #1433 holding.
Mirae Asset Global ETFs Holdings first reported a position in Nurix Therapeutics in Q2 2024 and has held it in 8 quarters since.
Mirae Asset Global ETFs Holdings's Nurix Therapeutics position peaked at $1.51M in Q4 2025.
195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q1 2026, filed 15 May 2026.